Predictors of real-world progression-free survival (rwPFS) in patients (pts) with epithelial ovarian cancer (EOC) treated with first-line maintenance (1LM) niraparib (nir): Post hoc analysis of the 1NSPIRE chart review study.
Journal of Clinical Oncology · 2026-05-28
Updated overall survival analysis and examination of subsequent therapy in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG-GY018 trial.
Journal of Clinical Oncology · 2026-05-27 · 1 citations
A phase 2, open-label, multi-center, single-arm study of atezolizumab and bevacizumab in the treatment of second line and beyond, recurrent/metastatic endometrial cancer.
Journal of Clinical Oncology · 2026-05-27
Vaginal Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network · 2026-02-09
Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network · 2025-12-01 · 13 citations
Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary
Gynecologic Oncology · 2025-11-05
PEMBROLIZUMAB PLUS ADJUVANT CHEMOTHERAPY WITH OR WITHOUT RADIOTHERAPY FOR NEWLY DIAGNOSED HIGH-RISK ENDOMETRIAL CANCER: HEALTH-RELATED QUALITY OF LIFE (HRQOL) FROM THE PHASE 3 ENGOT-EN11/GOG-3053/KEYNOTE-B21 STUDY
International Journal of Gynecological Cancer · 2025-11-01
SURVIVAL AND SAFETY OUTCOMES IN PART 1 OF THE ENGOT-EN6-NSGO/GOG-3031/RUBY TRIAL OF DOSTARLIMAB PLUS CARBOPLATIN-PACLITAXEL IN THE PRESENCE OF COMMON COMORBIDITIES
International Journal of Gynecological Cancer · 2025-11-01
Thematic cultural heritage tourism trail planning integrating multi-source data and machine learning in Wuhan China
npj Heritage Science · 2025-10-29 · 2 citations
Abstract A040: MYC-HSF1 coamplification as a biomarker for treatment sensitivity in high-grade serous ovarian cancer
Cancer Research · 2025-09-19
Frontline immunotherapy combined with radiation and chemotherapy in high-risk endometrial cancer (FIERCE)
Gynecologic Oncology · 2025-09-01
Machine learning approach for risk-based prediction of endometrial cancer recurrence
Gynecologic Oncology · 2025-09-01
Post hoc tipping point and multiple imputation analyses to determine the impact of early censored patients in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
Gynecologic Oncology · 2025-09-01
Patient-reported outcomes of phase III randomized, placebo-controlled study of pembrolizumab plus chemotherapy for advanced endometrial cancer (NRG GY018)
Gynecologic Oncology · 2025-09-01 · 1 citations
Real-world outcomes in patients with epithelial ovarian cancer who received first-line maintenance niraparib: Interim results from the 1NSPIRE chart review study
Gynecologic Oncology · 2025-09-01
Real-world clinical management of decreased platelet counts in patients with epithelial ovarian cancer who received first-line maintenance niraparib in the ACTIV1ZE study
Gynecologic Oncology · 2025-09-01
Predictive biomarkers for chemotherapy plus bevacizumab in recurrent/metastatic cervical cancer: The NRG Oncology/GOG-0240 National Institutes of Health Cancer Moonshot
Gynecologic Oncology · 2025-09-01
A plain language summary publication of patients’ survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel
Therapeutic Advances in Medical Oncology · 2025-09-01
1227eP Real-world (rw) outcomes in patients (pts) with epithelial ovarian cancer (EOC) who received first-line maintenance (1LM) niraparib: Final results from the 1NSPIRE chart review study
Annals of Oncology · 2025-09-01
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025
Journal of the National Comprehensive Cancer Network · 2025-08-01 · 43 citations